Migraine is a common neurological disorder affecting over 1 billion people worldwide, causing debilitating headaches often accompanied by light and sound sensitivity, nausea, and more. Despite its prevalence, the underlying causes of migraine remain incompletely understood.
In this video, Rune Häckert Christensen, MD, PhD-fellow discusses how human models of migraine have identified key molecular triggers like CGRP and PACAP, leading to a revolution in treatment. These discoveries have not only improved outcomes for many patients but also hold promise for those who don’t respond to current therapies.
Related content
Migraine is a prevalent neurological disorder characterized by recurrent and disabling attacks of moderate to severe headache
Migraine affects an estimated 1.1 billions worldwide and ranks as the 2nd leading cause of disability, while being the leading among young adults.
In human models of migraine, a suspected pharmacological migraine trigger is administered either orally or via infusion to a participant with migraine or a healthy volunteer, typically within a double-blinded, randomized, placebo-controlled design